文献速递前列腺癌

中危前列腺癌亚分类的国际多中心验证:根治性治疗未联合激素治疗

International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
PubMed 文献 · J Urol · 2019-01-01

该研究在3个学术中心纳入2550例接受根治性单药治疗(剂量递增外照射放疗、近距离放疗或根治性前列腺切除术)且未联合雄激素剥夺治疗的中危前列腺癌患者,验证NCCN中危亚分类(有利与不利)的预后价值。结果显示有利中危组10年远处转移率和前列腺癌特异性死亡率均显著低于不利中危组,提示对有利中危患者强化治疗 unlikely 带来有意义的肿瘤学获益。

要点

  • 有利中危前列腺癌根治性单药治疗后10年远处转移率低(0.2%-3.5%),不利中危组显著更高。
  • 有利中危组10年前列腺癌特异性死亡率0%-0.5%,不利中危组2.5%-5.6%。
  • 对有利中危患者,强化治疗不太可能显著改善肿瘤学结局。

核心结论

  • 该国际多中心研究独立验证了中危前列腺癌亚分类(有利与不利)在未接受雄激素剥夺治疗的根治性治疗患者中的预后价值。
  • 对有利中危前列腺癌患者,强化治疗不太可能带来有意义的肿瘤学获益。

研究设计与样本

  • 3个学术中心 pooled 数据,纳入2550例中危前列腺癌患者,均接受根治性单药治疗(剂量递增外照射放疗、近距离放疗或根治性前列腺切除术)且未联合雄激素剥夺治疗。
  • 有利中危1063例,不利中危1487例;根治性前列腺切除术1149例,剂量递增外照射放疗1143例,近距离放疗258例。
  • 采用竞争风险分析累积发生率评估生化复发、远处转移和前列腺癌特异性死亡率;不同治疗的中位随访时间60.4至107.4个月。

主要发现

  • 10年远处转移累积发生率:有利 vs 不利中危组,根治性前列腺切除术为0.2%(95%CI 0.2-0.2) vs 11.6%(95%CI 7.7-15.5),p<0.001。
  • 10年远处转移累积发生率:有利 vs 不利中危组,剂量递增外照射放疗为2.8%(95%CI 0.8-4.8) vs 13.5%(95%CI 9.6-17.4),p<0.001。
  • 10年远处转移累积发生率:有利 vs 不利中危组,近距离放疗为3.5%(95%CI 0-7.4) vs 10.2%(95%CI 4.3-16.1),p=0.063。
  • 10年前列腺癌特异性死亡率:有利 vs 不利中危组,根治性前列腺切除术为0%(95%CI 0-0) vs 3.7%(95%CI 1.7-5.7),p=0.016。
  • 10年前列腺癌特异性死亡率:有利 vs 不利中危组,剂量递增外照射放疗为0.5%(95%CI 0.5-0.5) vs 5.6%(95%CI 3.6-7.6),p=0.015;近距离放疗为0%(95%CI 0-0) vs 2.5%(95%CI 0.5-4.5),p=0.028。

关键数值与推荐

  • NCCN指南最近认可将中危前列腺癌亚分类为有利和不利亚组,但该亚分类原基于治疗异质性队列。
  • 本研究在未接受雄激素剥夺治疗的根治性单药治疗队列中验证该亚分类的预后价值。

临床怎么用

  • 对于有利中危前列腺癌患者,根治性单药治疗(手术、外照射放疗或近距离放疗)后远处转移和前列腺癌特异性死亡风险低。
  • 对有利中危患者,强化治疗(如联合雄激素剥夺治疗)不太可能显著改善肿瘤学结局,可考虑避免过度治疗。
  • 不利中危患者远处转移和前列腺癌特异性死亡风险显著更高,可能需要更积极的治疗策略。

局限性

  • 研究为多中心回顾性 pooled 数据分析,非前瞻性随机对照试验。
  • 不同治疗方式的中位随访时间范围较宽(60.4至107.4个月),可能存在随访偏倚。
  • 近距离放疗亚组样本量较小(258例),其组间比较(p=0.063)未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The NCCN Guidelines® recently endorsed a subclassification of intermediate risk prostate cancer into favorable and unfavorable subgroups. However, this subclassification was developed in a treatment heterogeneous cohort. Thus, to our knowledge the natural history of androgen deprivation treatment naïve favorable and unfavorable intermediate risk prostate cancer cases remains unknown. MATERIALS AND METHODS: Groups at 3 academic centers pooled data on patients with intermediate risk prostate cancer treated with radical monotherapy (dose escalated external beam radiotherapy, brachytherapy or radical prostatectomy) without combined androgen deprivation treatment. We used the cumulative incidence with competing risk analysis to estimate biochemical recurrence, distant metastasis and prostate cancer specific mortality. RESULTS: A total of 2,550 men at intermediate risk were included in study, of whom 1,063 and 1,487 were at favorable and unfavorable risk, respectively. Of the men 1,149 underwent radical prostatectomy, 1,143 underwent dose escalated external beam radiotherapy and 258 underwent brachytherapy. Median followup after the different treatments ranged from 60.4 to 107.4 months. The 10-year cumulative incidence of distant metastasis in the favorable vs unfavorable risk groups was 0.2% (95% CI 0.2-0.2) vs 11.6% (95% CI 7.7-15.5) for radical prostatectomy (p <0.001), 2.8% (95% CI 0.8-4.8) vs 13.5% (95% CI 9.6-17.4) for dose escalated external beam radiotherapy (p <0.001) and 3.5% (95% CI 0-7.4) vs 10.2% (95% CI 4.3-16.1) for brachytherapy (p = 0.063). The 10-year rate of prostate cancer specific mortality in the favorable vs unfavorable risk groups was 0% (95% CI 0-0) vs 3.7% (95% CI 1.7-5.7) for radical prostatectomy (p = 0.016), 0.5% (95% CI 0.5-0.5) vs 5.6% (95% CI 3.6-7.6) for dose escalated external beam radiotherapy (p = 0.015) and 0% (95% CI 0-0) vs 2.5% (95% CI 0.5-4.5) for brachytherapy (p = 0.028). CONCLUSIONS: This multicenter international effort independently validates the prognostic value of the intermediate risk prostate cancer subclassification in androgen deprivation treatment naïve cases across all radical treatment modalities. It is unlikely that treatment intensification would meaningfully improve oncologic outcomes in men at favorable intermediate risk.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Berlin A, Moraes FY, Sanmamed N, et al. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. J Urol. 2019. PMID: 30153435. doi:10.1016/j.juro.2018.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。